Acute Leukemias in children with Down syndrome

被引：38

作者：

Zwaan, Michel C. ^{[1
]}

Reinhardt, Dirk ^{[2
]}

Hitzler, Johann ^{[3
,4
]}

Vyas, Paresh ^{[5
,6
]}

机构：

[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-30625 Hannover, Germany

[3] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada

[4] Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada

[5] Univ Oxford, John Radcliffe Hosp, MRC, Mol Haematol Unit, Oxford OX3 9DS, England

[6] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2008年 / 55卷 / 01期

关键词：

D O I：

10.1016/j.pcl.2007.11.001

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Children with Down syndrome have an increased risk for developing both acute myeloid as well as lymphoblastic leukemia. These leukemias differ in presenting characteristics and underlying biology when compared with leukemias occurring in non-Down syndrome children. Myeloid leukemia in children with Down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms. Twenty percent of children. with transient leukemia subsequently develop myeloid leukemia. This transition offers a unique model to study the stepwise development of leukemia, and of gene dosage effects mediated by aneuploidy.

引用

收藏

页码：53 / +

页数：19

相关论文

共 83 条

[1] Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature [J].

Abildgaard, Lotte ;

Ellebaek, Eva ;

Gustafsson, Gran ;

Abrahamsson, Jonas ;

Hovi, Liisa ;

Jonmundsson, Gudmundur ;

Zeller, Bernward ;

Hasle, Henrik .

ANNALS OF HEMATOLOGY, 2006, 85 (05) :275-280

[2] Natural history of GATA1 mutations in Down syndrome [J].

Ahmed, M ;

Sternberg, A ;

Hall, G ;

Thomas, A ;

Smith, O ;

O'Marcaigh, A ;

Wynn, R ;

Stevens, R ;

Addison, M ;

King, D ;

Stewart, B ;

Gibson, B ;

Roberts, I ;

Vyas, P .

BLOOD, 2004, 103 (07) :2480-2489

[3] Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome [J].

Al-Ahmari, Ali ;

Shah, Niketa ;

Sung, Lillian ;

Zipursky, Alvin ;

Hitzler, Johann .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (06) :646-648

[4] Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric oncology group study [J].

Al-Kasim, F ;

Doyle, JJ ;

Massey, GV ;

Weinstein, HJ ;

Zipursky, A .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (01) :9-13

[5] Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952 [J].

Bassal, M ;

La, MK ;

Whitlock, JA ;

Sather, HN ;

Heerema, NA ;

Gaynon, PS ;

Stork, LC .

PEDIATRIC BLOOD & CANCER, 2005, 44 (01) :21-28

[6] Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 [J].

Becton, D ;

Dahl, GV ;

Ravindranath, Y ;

Chang, MN ;

Behm, FG ;

Raimondi, SC ;

Head, DR ;

Stine, KC ;

Lacayo, NJ ;

Sikic, BI ;

Arceci, RJ ;

Weinstein, H .

BLOOD, 2006, 107 (04) :1315-1324

[7] Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling [J].

Bourquin, JP ;

Subramanian, A ;

Langebrake, C ;

Reinhardte, D ;

Bernard, O ;

Ballerini, P ;

Baruchel, A ;

Cavé, H ;

Dastugue, N ;

Hasle, H ;

Kaspers, GL ;

Lessard, M ;

Michaux, L ;

Vyas, P ;

van Wering, E ;

Zwaan, CM ;

Golub, TR ;

Orkin, SH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (09) :3339-3344

[8] GATA transcription factors in hematologic disease [J].

Cantor, AB .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (05) :378-384

[9] Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party [J].

Chessells, JM ;

Harrison, CJ ;

Kempski, H ;

Webb, DKH ;

Wheatley, K ;

Hann, IM ;

Stevens, RF ;

Harrison, G ;

Gibson, BE .

LEUKEMIA, 2002, 16 (05) :776-784

[10] AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity [J].

Creutzig, U ;

Reinhardt, D ;

Diekamp, S ;

Dworzak, M ;

Stary, J ;

Zimmermann, M .

LEUKEMIA, 2005, 19 (08) :1355-1360

← 1 2 3 4 5 6 7 8 9 →